MetaCap

Opus Genetics Inc. (IRD)

NASDAQ: IRDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.99-0.09 (-2.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$385.65M
EPS (TTM)
-$1.48
52-week range
1.88 – 7.07
Day range
3.89 – 4.05
Volume / Avg
1.19M / 2.56M
Beta
—

52-week range

$1.88$7.07

IRD stock today

On Nov 20, IRD ended the session at $3.99, shedding $0.09 (2.21%), versus the S&P 500's 3.70% decline. Trading was light, with 1.19M shares changing hands, about 46% of the average daily volume. Shares are 43.6% below their 52-week high of $7.07, set on Sep 9, 2026 and 112.2% above the 52-week low of $1.88, in the middle of the past year's range.

IRD is up 98.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 108.9%. Opus Genetics has posted a net loss over the last twelve months (EPS of -$1.48), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Opus Genetics

Company profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. George Magrath M.B.A., M.D., M.S.
Headquarters
Durham, NC
Employees
27

Financial highlights

Full financials

In fiscal 2025, Opus Genetics generated $14.2 million in revenue, up 29.1% from fiscal 2024. Opus Genetics reported a net loss of $49.6 million, compared with a loss of $57.5 million a year earlier. Operating margin was -271.9%.

Opus Genetics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$14.20M$10.99M$19.05M$39.85M$589.00K
Growth+29.15%-42.30%-52.20%+6665.70%—
Net income$-49.59M$-57.53M$-9.99M$17.89M$-56.69M
EPS (diluted)$-0.80$-2.15$-0.46$0.87$-3.82

Analyst forecast

Forecast

Consensus (17 analysts)

strong_buy

Avg. price target

$13.94+249.37%

  • Strong buy 3
  • Buy 14
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.46 vs $-0.14
Surprise
-228.57%

IRD news

All IRD news

Opus Genetics peers

Health Care sector
IRD peer companies
CompanyPrice% ChgMarket capCompare
AVTXAvalo Therapeutics Inc.6.76+0.15%$390.88Mvs IRD
PHATPhathom Pharmaceuticals Inc.4.66-8.27%$378.82Mvs IRD
OCSOculis Holding AG7.06-5.11%$393.35Mvs IRD
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs IRD
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs IRD
PEPGPepGen Inc.3.78-3.82%$356.31Mvs IRD
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs IRD
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs IRD

Indexes, lists and sector

Opus Genetics stock FAQ

What is Opus Genetics's stock price today?

IRD last traded at $3.99 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.

Does Opus Genetics pay a dividend?

No. Opus Genetics does not currently pay a regular cash dividend.

Who is Opus Genetics's CEO?

Dr. George Magrath M.B.A., M.D., M.S. is the chief executive officer of Opus Genetics Inc., which has about 27 employees.

Has IRD ever split its stock?

Yes. The most recent IRD stock split was a 1-for-4 split on Nov 6, 2020, one of 3 splits on record.

What is the IRD 52-week high?

The 52-week high for IRD is $7.07 and the 52-week low is $1.88. The stock is currently 43.6% below its high.

Compare IRD